Boum et al. conducted a prospective, diagnostic accuracy study to evaluate the performance of four antibody-based rapid diagnostic tests (Innovita [Biological Technology; Beijing, China], Wondfo [Guangzhou Wondfo Biotech; Guangzhou, China], SD Biosensor [SD Biosensor; Gyeonggi-do, South Korea], and Runkun tests [Runkun Pharmaceutical; Hunan, China], and one antigen-based rapid diagnostic test (SD Biosensor [SD Biosensor; Gyeonggi-do, South Korea]) for community-based detection of SARS-CoV-2 infection in Cameroon. A total 1,195 participants were enrolled in the study between June 2nd and August 30th, 2020. Participants were either symptomatic with suspected COVID-19 or already began treatment (570 participants) or asymptomatic but presenting for screening voluntarily or from a contact tracing referral (625 participants). Antigen rapid diagnostic tests were compared with Abbot PCR testing and antibody rapid diagnostic tests were compared with Biomerieux immunoassays. Within the first seven days of symptom onset, antigen tests performed well, with a sensitivity of 80.0%. Antibody tests demonstrated low sensitivity (26.8%) during the first week of symptoms with sensitivity increasing to 76.4% 14 days after symptoms onset. For asymptomatic patients, sensitivity was 37.0% for antigen tests and 50.7% for antibody tests. A retrospective antigen-based algorithm demonstrated 94% sensitivity and 91% specificity among symptomatic patients and 34.0% sensitivity and 92.0% specificity among asymptomatic patients. These findings demonstrate the value of rapid diagnostics with testing algorithms as alternatives to PCR.